SCHEMBL14744943

SCHEMBL14744943

CCc1cc(C(=O)O)c(=O)[nH]c1-c1ccc2c(ccn2C)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRKAG1 P54619 2/20 0.40
PRKAA1 Q13131 2/20 0.40
PRKAB1 Q9Y478 2/20 0.40
PRKAA2 P54646 1/20 0.40
PTGER3 P43115 3/20 0.39
HSD11B1 P28845 1/20 0.38
CCNC P24863 2/20 0.38
CDK8 P49336 2/20 0.38
AR P10275 1/20 0.38
APP P05067 1/20 0.37
FASN P49327 1/20 0.36
CD274 Q9NZQ7 1/20 0.36
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
CYP2A6 P11509 1/20 0.35
PRKCI P41743 1/20 0.35
FAAH O00519 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14740960 0.91 PTGER3 (0.37) PRKAG1PRKAA1PRKAB1PRKAA2PTGER3
SCHEMBL14757657 0.88 KDM4E (0.39) PRKAG1PRKAA1PRKAB1PRKAA2PTGER3
SCHEMBL14741063 0.87 CYP19A1 (0.40) PTGER3FAAH
SCHEMBL14744763 0.87 BCL2 (0.36)
SCHEMBL27973067 0.85 PDE3B (0.36) PRKAG1PRKAA1PRKAB1PRKAA2CNR2
SCHEMBL14745763 0.83 PRKAG1 (0.32) PRKAG1PRKAA1PRKAB1PRKAA2
SCHEMBL14745825 0.83 MEN1 (0.42)
SCHEMBL14740948 0.83 PTGER3 (0.41) PRKAG1PRKAA1PRKAB1PRKAA2PTGER3
SCHEMBL14741124 0.82 USP7 (0.42) CCNCCDK8ARAPPBRD4
SCHEMBL14745318 0.81 APP (0.40) APPCREBBPCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US claimed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US claimed
CN-103889224-A ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC 2014-06-25 CN claimed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
WO-2016039937-A1 BICYCLIC AND TRICYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-03-17 WO disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
CN-103889224-A ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC 2014-06-25 CN disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP PRKAG1 3736/4885PRKAA1 2503/4885PRKAB1 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.